In the lead up to the Canadian legalization of cannabis edibles, Auxly Cannabis Group (TSXV:XLY,OTCQX:CBWTF) has elected to shift its management team by elevating Hugo Alves to the position of CEO.

Alves told the Investing News Network (INN) about the way the company plans to approach its biggest upcoming market development: the legalization of edibles and infused products in Canada.


Alves is replacing Chuck Rifici as CEO. Rifici, one of the co-founders of Canopy Growth (NYSE:CGC,TSX:WEED) and chairman of Auxly, will now have time to act entirely as an ambassador for the cannabis company and make sure Auxly’s partnerships are working correctly, according to Alves.

While a new top executive might lead to expectations of a new strategy for the company, Alves has been a steady presence with Auxly since the start; he said the plans for the company remain the same.

When it comes to the focus of the company, Alves knows October 17 represents a significant date for Auxly with the introduction of edibles and infused products in Canada.

The second stage of legalization, more commonly referred to as cannabis 2.0 or legalization 2.0, will allow all producers in the country to sell novelty items, such as vape pens and edible gummies.

All of these products are expected to produce returns of C$2.7 billion per year, according to Deloitte.

“We’re focused on bringing branded derivative products to consumers, to the cannabis 2.0 market. We’ve been focused on that now for probably well over a year,” Alves told INN.

The new CEO also identified this new legalization phase as a reset for the entire Canadian industry, which has struggled in the investment market as the rollout of adult-use products continues in Canada.

Edibles legalization opens door to brand partnerships

In July, Alves and Michael Lickver, senior vice president of strategy at Auxly, left their positions on the board of Dixie Brands (CSE:DIXI.U,OTCQX:DXBRF), an established partner of Auxly. Alves explained that this decision was planned ahead of his succession as Auxly’s CEO.

However, he confirmed there will be no change in direction between the two firms. Auxly holds the rights to Dixie products and it fully intends to bring those up north at the launch of legalization 2.0.

“We’ve got to make sure that the same Dixie product you buy in Denver, if you buy it in Canada it tastes the same (and) it feels the same,” Alves explained. He added that these products must still follow the regulatory guidelines of Canada compared to other US state-level markets.

Alves told INN the Dixie-branded products will not represent the bulk of edible and infused offerings the company plans to sell once these products become available in Canada.

“Dixie is another brand there and we will have a variety of SKUs for the Dixie brand. But in terms of us relying on the Dixie brand as our primary brand under which we offer derivative products, that won’t be the case,” he said.

In a previous interview with INN, Chuck Smith, CEO of Dixie, said it’s still too early to pinpoint which specific products will be initially available in Canada. However, the company wants all its products and brands to be available eventually.

Investor takeaway

In July, Auxly joined a select group of public marijuana firms when it confirmed a partnership with Imperial Brands (OTCQX:IMBBF,LSE:IMB), an established tobacco company with vast vaping technology.

The investment consists of a total deal worth C$123 million by way of a debenture structured in a three year term with a fixed annual interest rate of 4 percent.

Alves said this investment arrived at the perfect time for his company. He sees the transaction as more than an investment in Imperial Brands. The two firms will collaborate through Imperial’s vaping technology subsidiary, Nerudia, to expand the capabilities of Auxly in the Canadian market.

“I think it’s a huge validation for our vision, our assets and capabilities and strategy to execute on that vision,” said Alves. “And I think for the broader industry it really validates the tremendous growth opportunity that cannabis presents.”

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less